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Abstract
Background: While ETV6- NTRK3 fusion is common in infantile fibrosarcoma, NTRK1/3 fusion in pediatric tumors is
scarce and, consequently, not well known. Herein, we evaluated for the presence of NTRK1/3 fusion in pediatric
mesenchymal tumors, clinicopathologically and immunophenotypically.
Methods: We reviewed nine NTRK fusion-positive pediatric sarcomas confirmed by fluorescence in situ
hybridization and/or next-generation sequencing from Seoul National University Hospital between 2002 and 2020.
Results: One case of TPR-NTRK1 fusion-positive intracranial, extra-axial, high-grade undifferentiated sarcoma (12-
year-old boy), one case of LMNA-NTRK1 fusion-positive low-grade infantile fibrosarcoma of the forehead (3-year-old
boy), one case of ETV6-NTRK3 fusion-positive inflammatory myofibroblastic tumor (IMT) (3-months-old girl), and six
cases of ETV6-NTRK3 fusion-positive infantile fibrosarcoma (median age: 2.6 months, range: 1.6–5.6 months, M: F = 5:
1) were reviewed. The Trk immunopositivity patterns were distinct, depending on what fusion genes were present.
We observed nuclear positivity in TPR-NTRK1 fusion-positive sarcoma, nuclear membrane positivity in LMNA-NTRK1
fusion-positive sarcoma, and both cytoplasmic and nuclear positivity in ETV6-NTRK3 fusion-positive IMT and infantile
fibrosarcomas. Also, the TPR-NTRK1 fusion-positive sarcoma showed robust positivity for CD34/nestin, and also
showed high mitotic rate. The LMNA-NTRK1 fusion-positive sarcoma revealed CD34/S100 protein/nestin/CD10
coexpression, and a low mitotic rate. The IMT with ETV6-NTRK3 fusion expressed SMA. Six infantile fibrosarcomas
with ETV6-NTRK3 fusion showed variable coexpression of nestin (6/6)/CD10 (4/5)/ S100 protein (3/6).
Conclusions: All cases of NTRK1 and NTRK3 fusion-positive pediatric tumors robustly expressed the Trk protein. A
Trk immunopositive pattern and CD34/S100/nestin/CD10/SMA immunohistochemical expression may suggest the
presence of NTRK fusion partner genes. LMNA-NTRK1 fusion sarcoma might be a low-grade subtype of infantile
fibrosarcoma. Interestingly, more than half of the infantile fibrosarcoma cases were positive for S100 protein and
CD10. The follow-up period of TPR-NTRK1 and LMNA-NTRK1 fusion-positive tumors are not enough to predict
prognosis. However, ETV6-NTRK3 fusion-positive infantile fibrosarcomas showed an excellent prognosis with no
evidence of disease for an average of 11.7 years, after gross total resection of the tumor.
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Background
Next-generation sequencing (NGS) studies have recently
revealed an increasing number of fusion genes in soft
tissue sarcomas; these genes have been identified as
oncogenic drivers and diagnostic markers of a wide
range of adult and pediatric cancers [1]. However, until
now, the clinicopathological characteristics of all these
gene fusion tumors have not been clarified.
Among these recent discoveries are neurotrophic
receptor kinase (NTRK) gene fusions. NTRK1, NTRK2,
and NTRK3 encode the neurotrophic tyrosine kinase
receptor family TrkA, TrkB, and TrkC transmembrane
proteins [2]. These genes play an essential role in
nervous system development and function through
activation by neurotrophins [3]. However, NTRK gene
fusions transcribe to chimeric Trk proteins either by con-
stitutive activation or overexpression of kinase-conferring
oncogenic proteins [2]. The erythroblast transformation-
specific (ETS) variant 6 (ETV6)-neurotrophic receptor
kinase (NTRK3) fusion has been identified in glioblastoma,
mammary secretory carcinoma, salivary gland mammary
carcinoma, adult lung cancer, papillary thyroid cancer, and
mesenchymal tumors including infantile fibrosarcoma,
mesoblastic nephroma, IMT, and gastrointestinal stromal
tumors [1, 2, 4–8]. Echinoderm Microtubule Associated
Protein like-4 (EML4)-NTRK3 fusion has also been identi-
fied in infantile fibrosarcomas and congenital mesoblastic
nephroma, in addition to ETV6-NTRK3 fusion [9]. The
common fusion partners of NTRK1, located on 1q25, are
the 5′ exons of various thyroid-expressed genes (tropomy-
osin 3 [TPM3], translocated promoter region, nuclear
basket protein [TPR], and TRK-fused gene [TFG]) in the
frame on 1q21–23 because NTRK1 is located close to
its gene partners [10]. Additional fusion partners of
NTRK1 include RAB GTPase activating protein 1-like
(RABGAP1L), chromatin target of Protein Arginine Methyl-
transferase 1 (PRMT1) (CHTOP), Rho-Rac guanine nucleo-
tide exchange factor 2 (ARHGEF2), neurofascin (NFASC),
and brevican (BCAN) [11].
TPR-NTRK1 fusion has been identified in infantile
fibrosarcoma [8], pediatric papillary thyroid carcinomas
[12], lipofibromatosis [13, 14], interdigitating dendritic
cell sarcoma [5], fibrosarcoma-like uterine undifferenti-
ated sarcomas [1], and colorectal adenocarcinomas
(Supplementary file: Table 2) [15]. However, it has never
been reported in primary intracranial tumors [5].
Additionally, lamin A/C (LMNA)-NTRK1 fusion has been
infrequently reported in congenital infantile fibrosarcoma
[4, 16–18], cellular mesoblastic nephroma [19], and
lipofibromatosis-like neural tumors [14].
We have recently encountered pediatric cases of intra-
cranial and forehead sarcomas. Pathologically, they did not
fit into any known category of sarcomas or benign mesen-
chymal tumors. However, RNA sequencing by NGS of our
cases revealed the presence of TPR-NTRK1, LMNA-
NTRK1, and ETV6-NTRK3 fusions. Herein, we report
these notable cases in detail so that their clinicopathologi-
cal characteristics can be defined.
Materials and methods
Patients
Nine pediatric NTRK fusion-positive sarcomas were re-
trieved from the archives of the Department of Pathology,
Seoul National University Children’s Hospital from 2002 to
2019. The fusion genes were detected by either fluorescence
in situ hybridization (FISH) or NGS, such as RNA sequen-
cing or customized gene panel study. One case of ETV6-
NTRK3 fusion-positive IMT, one case of TPR-NTRK1
fusion-, one case of LMNA-NTRK1 fusion- and six cases of
ETV6-NTRK3 fusion-positive sarcomas were reviewed.
Pathology, immunohistochemistry (IHC), and FISH
All tumors were reviewed by two pathologists (JWK and
SHP). IHC stains were performed on an immunostaining
system (BenchMark ULTRA system, Ventana-Roche,
Mannheim, Germany) using primary antibodies including
Trk (1: 50, Cell signaling, Boston, USA), nestin (1: 200,
Millipore, Temecula, USA), vimentin (1: 500, DAKO,
Grostrup, Denmark), S100 protein (1: 3000, DAKO), CD34
(1: 200, Dako), CD10 (RTU, Novocastra, Newcastle, UK),
Ki67 (1: 100, MAb MIB-1; Dako), phosphohistone-H3
(pHH3, 1: 5000, Cell Marque, Rocklin, USA), Transducin-
like enhancer of split 1 (TLE1, 1: 20, Cell Marque, Rocklin,
US), Fli1 (1: 300, Becton and Dickinson, Flanklin Lakes,
US), p53 (1: 100, DAKO), ERG (rtu, Ventana, Export, US),
CD99 (1: 200, Novocastra (Leica), Muchen, Germany),
smooth muscle actin (SMA, 1: 500, DAKO), desmin (1:200,
DAKO), myogenin (1: 500, DAKO), cytokeratin (CK, 1:
300, DAKO), epithelial membrane antigen (EMA, 1: 300,
DAKO), integrase interactor 1 (INI-1, 1: 100, Cell signaling,
), and Signal transducer and activator of transcription 6
(STAT6, 1: 100, ABCAM, Cambridge, UK) (Suppelemen-
tary Table 1). Appropriate positive controls were included,
and for the negative control, primary antibodies were omit-
ted. Mitotic activity was assessed with pHH3 immunostain
on 4 μm thick formalin-fixed, paraffin-embedded (FFPE)
slides by counting mitotic figures in 10 high power fields
(HPF; area, 2.38mm2).
For ETV6 break-apart FISH study, locus-specific identi-
fier (LSI) Vysis ETV6 fluorescence dual-color break apart
DNA probes, ETV6 [Centromeric (CEN)] SpectrumGreen
and Vysis LSI ETV6 [Telomeric (TEL)] SpectrumOrange
(Abbott Molecular, Abbott Park, US) were used.
DNA extraction and customized brain tumor gene panel
study
On hematoxylin and eosin-stained FFPE sections, repre-
sentative areas of tumors with at least 90% tumor cell
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purity were outlined for microdissection. DNA-extraction
from the serial sections of the microdissected tumor
tissue using the Maxwell® RSC DNA FFPE Kit (Pro-
mega, USA) was carried out according to the manufac-
turer’s instructions.
The customized targeted gene panel (FIRST brain
tumor panel and FIRST pan-cancer panel), which was
customized and verified by the Department of Pathology
of Seoul National University Hospital (SNUH), was used,
containing 172 genes and ten fusion genes, and with a
1.7Mb/run by NextSeq550Dx in Hi-Output. The pro-
duced sequencing data was analyzed using the pipeline
of SNUH First Brain Tumor Panel Analysis. First, we
performed the quality control of the Fastq file and
analyzed only the data that passed the criteria. Paired-
end alignment to the hg19 reference genome was
performed using BWA-men and the GATK Best Practice
[20]. After finishing the alignment step, an “analysis-
ready BAM” was produced, and second quality control
was performed to determine if further variant calling is
appropriate. In the pipeline, single nucleotide variation
(SNV), insertion and deletion (InDel), copy number
variation (CNV), and translocation, were analyzed using
at least more than two analysis tools, including in-house
and open-source software. The open-source tools used
were GATK UnifiedGenotyper, SNVer and LoFreq for
SNV/InDel detection [21], Delly and Manta for Trans-
location discovery [22], THetA2 for purity estimation,
and CNVKit for CNV calling [23], respectively. SnpEff
was used to annotate the variants detected from various
databases such as RefSeq, COSMIC, dbSNP, ClinVar,
and gnomAD. The germline variant was then filtered
using the population frequency of these databases (> 1%
population frequency). Finally, the variants were con-
firmed through a comprehensive review of a multidiscip-
linary molecular tumor board.
RNA extraction, RNA sequencing, and fusion analysis
For RNA sequencing, the tumor RNA was extracted
from the paraffin block (tumor fraction: > 90%) with
Maxwell® RSC RNA FFPE Kit (Promega, USA). The
library was generated with SureSelectXT RNA Direct Kit
(Agilent, Santa Clara, USA), and sequenced on an
Illumina NovaSeq 6000 at Macrogen (Seoul, Republic of
Korea). Raw sequencing reads were analyzed with three
kinds of algorithms, namely: DIFFUSE, Fusion catcher,
and Arriba (https://github.com/suhrig/arriba/), to detect
gene fusions. The results were then compared.
Fastq files were briefly aligned by the STAR aligner on
the hg19 reference genome for Arriba analysis. The
Fig. 1 a-e Case 1 with TPR-NTRK1 fusion.: MRI reveals a) T1-low, b-d) T2-high dura-based mass with enhancement. e The tumor was located in
the right temporal convexity and right cerebellar tent (The direction of the brain mentioned as cephalhead and posterior). The inlet is the cut
surface of the tumor showing yellowish, and solid without hemorrhage or necrosis. f, g Case 2 with LMNA-NTRK1 fusion tumor: T2 weighted MRI
revealed low-density mass on the left forehead. The cut surface of the tumor shows a gray-white solid appearance without hemorrhage
or necrosis
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chimeric alignments file and the read-through align-
ments file were produced, and fusion candidates were
generated with a set of filters that detect artifacts based
on various characteristic features.
Result
Clinicopathological findings and follow-up data of the
patients
The patient with TPR-NTRK1 fusion-positive sarcoma
was a 12-year-old boy who presented with headache and
diplopia for 3 months, and did not have any perinatal
health problems. A 7.4-cm contrast-enhancing mass was
detected in the right temporal lobe on magnetic reson-
ance imaging (MRI) (Fig. 1a-d). Craniotomy revealed a
hypervascular, extra-axial tumor with superficial brain
invasion (Fig. 1e). Complete resection of the tumor with
adjuvant chemotherapy with Ifosfamide, Carboplatin, and
Etoposide (ICE) and radiation therapy (54 + 7.2 Gy) were
administered because the pathology was high-grade un-
differentiated sarcoma.
The patient with LMNA-NTRK1 fusion-positive
sarcoma was a 3-year-old boy who presented with a grow-
ing mass on his left forehead, which had been present
since he was a neonate as a pea-sized mass, and it has
recently grown rapidly to 4.0 × 3.5 × 3.0 cm. It protruded
from the forehead and was covered with eroded skin. The
patient underwent complete surgical excision, and the cut
surface of the tumor exhibited a homogenous tan-colored
solid appearance (Fig. 1f-g).
The patient with ETV6-NTRK3 fusion-positive IMT was
a 3-month-old girl who presented with sudden onset dys-
pnea and systemic cyanosis. Chest computerized tomog-
raphy (CT) showed a mass on the left lower thorax, that
looked like a mass of the lower lobe of the left lung (Fig. 2).
The mass was embolized under the impression of arterio-
venous malformation at the local hospital. However, the
symptom and signs were not relieved, and the mass had
grown continuously to 5.6 × 5.2 × 3.3 cm. Lobectomy of the
left lower lobe was then conducted to remove the tumor.
Grossly, the mass was well-encapsulated and well-separated
from the left lower lobe of the lung (Fig. 2). The tumor
arose from an extrapulmonary sequestration, and was diag-
nosed as IMT by full pathological examination and NGS
(using the customized First pan-cancer gene panel).
The median age of the six ETV6-NTRK3 fusion-positive
infantile fibrosarcoma patients were 2.6 months (range:
1.6–5.6months of age) at the time of surgery. The male to
female ratio was 5: 1. The patients had presented with a
mass on the tongue, buttock, right shoulder, left foot, right
abdominal cavity, and sacrococcygeal area, respectively.
Fig. 2 a Chest CT of the ETV6-NTRK3 fusion-positive inflammatory myofibroblastic tumor (IMT) reveals a heterogeneously enhancing tumor in the
left lower part of the thorax. b The mass arises from extrapulmonary sequestration, supplied by the left phrenic artery, which is separated from
the lower lobe of the lung. c The cut surface of the tumor is hemorrhagic and has congested large vessels. d This is the microscopic picture of
the squared part of Fig. c. It is a well-encapsulated, but partly adhered to the lower lobe of the left lung. The tumor pushed the left lower lobe of
the lung. Hemorrhage was developed by previous embolization of large vessels of the sequestrated lung, under the impression of
arteriovenous malformation
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Five tumors were completely resected, and adjuvant
chemotherapies were given, as summarized in Table 1.
The remaining massive sacrococcygeal tumor, involving
the spinal cord, was initially subtotally resected and
underwent three operations with one cycle of chemother-
apy, but the patient was lost to follow-up.
The follow-up data are summarized in Table 1. The
patients with TPR-NTRK1 and LMNA-NTRK1 fusion-













Age/Gender 12 y/ male 3 y/ male 6 mo/female Median age: 2.6 months
(range: 1.6 ~ 5.6 months),
M: F = 5:1
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biggest diameter
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Mitotic rate 25/10 HPFs 0/10 HPFs 1/ 10 HPFs 10/10HPFs ~ 40/10 HPFs
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1 patient: Follow-up loss
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Infantile fibrosarcoma Infantile fibrosarcoma,
inflammatory
myofibroblastic sarcoma
NED No evidence of disease
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positive sarcomas fared relatively well, with no tumor
recurrence or neurological defects, during the 18months
and 11.6 months follow-up period, respectively. Five
patients with ETV6-NTRK3 fusion-positive infantile
sarcomas are all alive without disease for an average of
11.7 years (range: 6.0–17.4 years), but one case who had
a huge sacrococcygeal mass was lost to follow-up.
Result of pathology, IHC, and FISH
Histopathology of the TPR-NTRK1 fusion-positive
sarcoma showed a sheet of small oval-to-spindle cells with
dilated blood vessels. Scanning power microscopy revealed
a tiger-striped pattern due to vague layers of cellular and
less-cellular areas with keloid type collagen deposits
(Fig. 3). The tumor cells exhibited relatively uniform oval
nuclei with fine chromatin and clear-to-eosinophilic cyto-
plasm. A high mitotic rate (25/10 per high-power fields)
and a high Ki-67 labeling index (36.0%) were present;
however, necrosis was not observed. The tumor cells were
also robustly positive for Trk (1: 50, Cell Signaling, Boston,
US), CD34, nestin, p53, and vimentin (Fig. 4). The robust
nuclear positivity of Trk was remarkable (Fig. 5). However,
the tumor cells were negative for S-100 protein, SMA,
desmin, myogenin, CD99, Fli-1, CD56, STAT6, CK and
EMA. TLE1 was weakly positive for the tumor cell nuclei
and INI1 was retained.
The LMNA-NTRK1 fusion-positive tumor was com-
posed of vaguely fascicular spindle cells with bland-looking
elongated nuclei and inconspicuous nucleoli (Fig. 3c).
There was collagen laid down between the tumor cells.
Intermixed inflammatory cell infiltration was remarkable,
which was pronounced on CD3 IHC (Fig. 4e). The Ki-67
index was moderately high (18.2%), but many of them
might be infiltrating inflammatory cells. Mitosis was absent
on pHH3 IHC. There was neither necrosis nor
hemorrhage. Therefore, this tumor was much less cellular
and much more bland-looking than TPR-NTRK1 or ETV6-
NTRK3 fusion-positive sarcoma. The tumor cells were ro-
bustly and diffusely positive for Trk, S100-protein, CD34,
and nestin (Figs. 4 and 5), but negative for CD56, SMA,
desmin, myogenin, STAT6, EMA, CK, CD1a, CD21,
CD35, CD43, WT-1(c-terminal), MelanA, HMB45, BRAF,
and ALK. The nuclear envelope-positivity for Trk was
remarkable with weak cytoplasmic staining (Fig. 3).
The ETV6-NTRK3 fusion-positive IMT was composed of
vaguely fascicular bland-looking spindle cells intermixed
with lymphoplasma cells (Figs. 2 and 3). The tumor cells
were positive for Trk and SMA, but negative for S100,
CD34, ALK, CD10, desmin, myogenin, CD99, CD56, CK,
EMA, and STAT6. There was no necrosis. Mitosis was very
low (1/10HPF), but the Ki-67 index was 36%, possibly due
to the presence of inflammatory cells. ETV6 break FISH
Fig. 3 a Histology of the intracranial undifferentiated sarcoma with TPR-NTRK1 fusion shows alternating cellular areas with collagen bands show a
tiger pattern-like appearance. The tumor cells are oval to short spindle cells. b The forehead mesenchymal tumor with LMNA-NTRK1 fusion shows
relatively low cellular spindle cell mesenchymal tumor with keloid type collagen laydown. c The pulmonary inflammatory myofibroblastic tumor
with ETV6-NTRK3 fusion shows bland-looking spindle cells with intermixed lymphoplasma cells. d A sacrococcygeal infantile fibrosarcoma with
ETV6-NTRK3 fusion shows fascicular spindle cells with high cellularity (a-d: H&E, bar: a: 300, μm, b-d: 50 μm)
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was positive and pan-cancer panel resulted in ETV6-
NTRK3 fusion (split read: 339, spaning read: 40).
The histopathology of ETV6-NTRK3 fusion-positive
sarcomas showed highly cellular and relatively uniform
small spindle cells with a high mitotic rate (10–40/10
HPFs). There was neither necrosis nor prominent in-
flammatory cell infiltration in all cases. These infantile
fibrosarcomas were diffusely and robustly positive for
Trk (100%), S100 protein (50%, 3/6 cases), nestin, CD10
(80%, 4/5 cases), and vimentin (100%), but negative for
CD34, SMA, desmin, myogenin, and CD56. The Trk
IHC showed a diffuse cytoplasmic stain with some
nuclear staining (Fig. 5). Ki-67 labeling indices were 15–
60%. ETV6-NTRK3 fusion was verified by FISH in all six
cases (Fig. 5) and crosschecked by RNA sequencing in
two cases.
TPR-NTRK1 fusion was double-checked by targeted
DNA gene panel and RNA sequencing. The targeted
gene panel revealed a TPR-NTRK1 fusion of TPR on
chromosome 1q25 (position 186,337,018) and NTRK1
on chromosome 1q21-q22 (position 156,844,363) with
amplification of NTRK1 (copy number: 11) and
H3F3A (copy number: 12) on chromosome 1 in case
1 (Fig. 6).
RNA sequencing of an intracranial sarcoma (12-year-
old boy) confirmed the presence of TPR-NTRK1 fusion
(Breakpoint: 1: 186337018, 1: 156844363). RNA sequen-
cing of a forehead tumor (3-year-old boy) confirmed
the presence of LMNA-NTRK1 fusion (Breakpoint: 1:
156104766, 1: 156844698). The number of split reads in
TPR and NTRK1 was 35 and 31, respectively, with two
discordant mates, and 37 split reads in LMNA and 53
in NTRK1, with seven discordant mates. RNA sequen-
cing performed in two cases of infantile fibrosarcoma
showed ETV6-NTRK3 fusion (Case 4). The breakpoints
and split reads of ETV6 and NTRK3 (Breakpoints: 12:
12022903: 15: 88483984, 12: 12022903, 15: 88524591)
were 11 and 16, and 25 and 8, respectively
Fig. 4 a, b Sarcoma with TPR-NTRK1 fusion shows co-positive for nestin and CD34. c, d ETV6-NTRK3 fusion-positive infantile fibrosarcoma is co-
positive for S100 protein and CD10. e-h The LMNA-NTRK1 fusion sarcoma has lots of CD3-positive T-cell infiltration and robustly coexpressed
CD34, S100, and CD10. (a: nestin, b, f: CD34, c, g: S100 protein, e: CD34D, h: CD10, Bar: 200 μm)
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(Supplementary Fig. 1-4). Split reads are the read frag-
ments of the unmatched paired-end alignments. A dis-
cordant alignment happens when both mates align
uniquely, but does not satisfy the paired-end constraints.
Discussion
Primitive small round cell sarcomas and infantile fibrosar-
comas are rare childhood sarcomas that pose diagnostic
and therapeutic challenges. Recently, confirmative diagnosis
of neoplasms has been made possible at the genomic level
by identification of driver mutation or marker gene
alterations [24]. Recent reports have described emerging
pediatric fusion-positive sarcomas, including NTRK [5, 8,
25, 26]. Our NTRK fusion-positive pediatric sarcomas have
distinct immunohistochemical profiles. The TPR-NTRK1
fusion-positive tumor was a CD34-positive, dural-based,
high-grade undifferentiated sarcoma with features that did
not fit the classifications of existing types of sarcoma. In
contrast, our LMNA-NTRK1 fusion-positive tumor was a
low-grade spindle cell mesenchymal tumor of the forehead
that was first noticed early in the neonatal period. The
LMNA-NTRK1 fusion-positive tumor was difficult to
diagnose before RNA sequencing by NGS because of its
unusual pathology and immunohistochemical profile,
namely, a combination of prominent inflammatory cells, no
mitotic activity (0/10 HPF), and S100/CD34 coexpression.
However, Hung et al.’s case of infantile fibrosarcoma also
showed prominent inflammatory cells [4]. S100-protein
and CD34 co-positivity are generally rare in sarcomas; these
can be interpreted as hybridomas or evidence of dual
differentiation. However, infantile fibrosarcomas often show
coexpression of these two antibodies [16, 27]. Miettinen
et al. and Wong et al. reported a non-pleomorphic,
low-grade spindle cell neoplasm with LMNA-NTRK1
fusion, that was diagnosed as infantile fibrosarcoma
[17, 27]. Miettinen et al. ‘s case showed low mitotic
rates (< 5/10 HPFs), and S100 protein/CD34-coexpres-
sion [27]. Wong et al.’s case was CD34/vimentin-posi-
tive [17]. Our LMNA-NTRK1 fusion-positive sarcoma
was consistent with Hung et al.’s and Miettinen
et al.’s infantile fibrosarcoma with S100 protein/CD34
coexpression. The main differential diagnosis of this
LMNA-NTRK1 fusion tumor was IMT because of
prominent inflammatory cells in the tumor, but it can
be ruled out based on its immunoprofile (SMA-nega-
tive, with S100/CD34 coexpression).
NTRK1 encodes TRKA receptor tyrosine kinase, which
has a high affinity for nerve growth factor [3]. Genetic
alterations of NTRK1 by translocations, amplifications,
deletions, and point mutations have been reported in
various tumor types, suggesting the potential role of Trk
in oncogenesis [28, 29]. More recently, NTRK1 chromo-
somal rearrangements have been identified in additional
tumor types (Supplementary file, Table 2) [10, 21, 30,
Fig. 5 Trk immunohistochemistry shows a Nuclear positivity in TPR-NTRK1 fusion sarcoma (Case 1), bmostly nuclear membrane, and cytoplasmic stain in
LMNA-NTRK1 fusion sarcoma (Case 2). and c mainly cytoplasmic stain in ETV6-NTRK3 fusion sarcoma. In Fig. b, the Trk-negative cells are infiltrating
inflammatory cells (a-c: Trk IHC, lower bar: 50 μm). d. locus-specific identifier (LSI) FISH study using ETV6 fluorescence dual-color break apart DNA probes
show one fused and one widely separated SpectrumGreen and SpectrumOrange signals in an infantile fibrosarcoma with ETV6-NTRK3 fusion-positive
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31], suggesting that while oncogenic activation through
NTRK1 fusion is not frequent, it can occur in various
cancers. Interestingly, a significant number of NTRK1-
associated gene fusions have developed as a result of
intrachromosomal gene fusion [11]. Depending on the
directions of transcription of NTRK1 and its fusion
partner, intrachromosomal fusions can occur either
through simple interstitial deletion (e.g., LMNA-NTRK1)
or through a more complex break/inversion mechanism
(e.g., TPM3-NTRK1 or TPR-NTRK1), if the two genes
are transcribed in opposite directions [13]. A 737-kbp
deletion yielded the 5′ end of LMNA (localized to 1q22),
including exons 1–10 fused to the 3′ end of NTRK1
(also localized to 1q22) and exons 12–17 [17].
Pan-Trk IHC can be used to detect NTRK fusion tu-
mors; however, the expression site within the tumor cell
differs according to the fusion partner genes [4]. We
found strong nuclear envelope and cytoplasmic positivity
in our LMNA-NTRK1 fusion-positive tumor. Intense nu-
clear staining in our TPR-NTRK1 fusion-positive sar-
coma was observed with Trk (clone A7H6R) IHC, which
is consistent with Hechtman et al. ‘s report using mono-
clonal antibody [MAb] EPR17341 [32]. However, a dif-
fuse and strong cytoplasmic staining with MAb
EPR17341 was reported in both LMNA-NTRK1 fusion-
positive tumor and TPM3-NTRK1 fusion-positive sar-
coma [1, 33]. Davis et al. reported nuclear positivity in
NTRK3 fusion tumors and cytoplasmic positivity in
NTRK1/2 fusion tumors using the panTrk IHC
(EPR17341) [8]. These differences in immunopositivity
might be due to different Trk antibody clones and differ-
ent types of sarcomas.
ETV6-NTRK3 and (rarely) EML4-NTRK3, LMNA-
NTRK1, TPM3-NTRK1, and SQSTM1-NTRK1 fusions
have been reported in infantile fibrosarcomas (Table 1)
[4, 8, 16]. The six cases of classic infantile fibrosarcoma
and one IMT in our study had an ETV6-NTRK3 fusion
verified by ETV6 break-apart FISH and/or RNA sequen-
cing. The diffuse cytoplasmic Trk positivity in our cases
is consistent with the Trk immunopositivity patterns in
ETV6-NTRK3 fusion-positive tumors from previous
reports [4, 27].
Although ETV6-NTRK3 is a genetic hallmark of infantile
fibrosarcoma, it has also been reported in ALK-negative
IMTs. So far, six cases of ETV6-NTRK3 fusion-positive
IMTs have been published [5–7]. Chang et al. reported
that ALK-altered thoracic IMTs were 73% (24/33), and the
remaining ALK-negative IMTs had ROS1 fusion (15%, 5
Fig. 6 The custom NGS panel revealed TPR-NTRK1 fusion (IGV capture)
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cases) or ETV6-NTRK3 fusion (9%, 3 cases) or RET fusion
(3%, 1 case) [6]. Our IMT case is unique because it oc-
curred in the extrapulmonary sequestered lung, had ETV6-
NTRK3 fusion, and is the youngest reported ETV6-NTRK3
fusion-positive IMT in the literature [34]. The previously
reported youngest patient with ETV6-NTRK3 fusion-
positive IMT was 2 years old [6].
These NTRK fusion tumors tend to respond to NTRK
inhibitors [2, 11]. LOXO-101 is an orally bioavailable
tyrosine kinase inhibitor that inhibits Trk catalytic activ-
ity with a low nanomolar potency. A phase 1 study with
LOXO-101 in soft tissue sarcoma with LMNA–NTRK1
fusion and non-small cell lung cancer harboring TPR-
NTRK1 fusion showed a good response [35, 36].
Crizotinib was a durable response in the LMNA-NTRK1
fusion-positive undifferentiated pleomorphic sarcoma
[37]. NTRK gene fusion could be a novel target of NTRK
inhibitors for multiple tumor types [2].
In conclusion, we report two cases of NTRK1 fusion-
positive and seven cases of NTRK3 fusion-positive
pediatric sarcomas and IMT that were diagnostically
challenging without molecular features. These three
types of fusion-positive mesenchymal tumors (TPR-
NTRK1, LMNA-NTRK1, and ETV6-NTRK3) differed in
their H&E morphology, immunoprofile, and Trk immu-
nopositivity patterns. In the case of LMNA-NTRK1
fusion sarcoma, S100/CD34/CD10-coexpression was a
novel finding. The S100 protein, nestin, and CD10 posi-
tivity in infantile fibrosarcoma was also a new finding.
The TPR-NTRK1 fusion sarcoma was positive for CD34
and nestin but negative for S100 protein. Thus, the Trk
and CD34/S100/nestin/CD10 immunophenotype could
be used for differential diagnosis. The sacrococcygeal
infantile fibrosarcoma was unable to achieve complete
resection, and the exact outcome is unknown because
the patient was lost to follow-up. However, the
remaining patients with ETV6-NTRK3 fusion-positive
infantile fibrosarcomas survived for up to 17.3 years
(median survival: 8.3 years), without tumor recurrence,
after complete resection of the tumor. The patients
with these fusion-positive tumors may benefit from
NTRK inhibitor therapy if the tumors cannot be con-
trolled by conventional treatment [38].
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